ArticleCancer medicine2026
Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The survival benefit of neoadjuvant chemotherapy (Neo-CT) among male breast carcinoma (MaBC) remains unclear, and the specific population that can benefit from Neo-CT is also not yet defined. We utilized the data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database and employed Kaplan-Meier analysis; Cox proportional hazards model and binary variable Logistic regression were performed to evaluate the effect of Neo-CT on the therapeutic response and prognosis of MaBC patients. Among the 4171 MaBC subjects included, 194 (4.7%) patients received Neo-CT only (Neo-CT only group), 246 (5.9%) cases received adjuvant chemotherapy and Neo-CT (CT + Neo-CT group); the remaining 3731 (89.5%) cases received postoperative chemotherapy only (CT-only group). Totally, 20 (12.12%) participants achieved pathological complete response (pCR). And patients who achieved a pCR (pCR subgroup) had improved 5-year and 10-year overall survival (OS) (100.0% vs. 79.70% vs. 73.81%, 100.0% vs. 59.12% vs. 28.82%, respectively) and breast cancer-specific survival (BCSS) (86.30% vs. 91.49%, 69.04% vs. 83.32%, respectively) in comparison with those in the Non-pCR subgroup. Further binary Logistic regression analysis showed that the achievement of pCR might be related to stage I-II (p = 0.007) and hormone receptor (HR) negative (p = 0.010) disease, and the pCR rate of stage I-II and HR- MaBC patients was 66.67%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.